SPECIAL SEMINAR - Dr. Guadalupe SUAREZ - INSERM U1236 MOBIDIC RENNES
"Epigenetic regulation of anti-tumoral CD8+ T cell responses against transposable elements in mature B-cell Lymphomas"
Martes 19 enero 2027, 11:00

200
"Epigenetic regulation of anti-tumoral CD8+ T cell responses against transposable elements in mature B-cell Lymphomas"
Dr. Guadalupe SUAREZ
MCF University of Rennes and INSERM U1236 MOBIDIC RENNES
Abstract
Follicular lymphoma (FL) and large B-cell lymphoma (LBCL) account for over 70% of all lymphoma cases and frequently exhibit mutations in epigenetic regulators such as KMT2D, CREBBP and EZH2, but the impact of these mutations on the recognition of tumor cells by CD8+ T cells is poorly understood. Additionally, transposable elements (TE), which are normally silenced by epigenetic mechanisms, may become re-expressed in cancer, leading to the production of TE-derived neoantigens that can be recognized by the immune system.
Our group investigates how mutations in epigenetic regulators impact CD8+ immune responses in B cell lymphomas with a focus on CD8+ T cell responses to TE-derived antigens, in both patient samples and mouse models. By combining RNAseq analysis of large patient cohorts with immunopeptidomic analyses, we found sets of TEs overexpressed in tumoral B cells that can give rise to peptides presented in MHC-I molecules in B lymphoma samples, showing that TE-derived peptides can be presented in MHC-I molecules in B lymphoma samples. We also found that mutations in KMT2D, CREBBP and EZH2 impact TE expression in FL patient tumors and that treatment of B lymphoma cell lines with the EZH2 inhibitor Tazemetostat, induces the overexpression of specific sets of TEs on EZH2 gain of function mutated cell lines.
To assess the impact of KMT2D mutations on immune responses in B cell lymphomas, we have developed a transplantable syngeneic LBCL mouse model mutated for KMT2D. Analysis of TE expression shows that KMT2D deficiency impacts the expression of several hundreds of TEs. Finally, preliminary results show that KMT2D deficiency reduces tumor-specific CD8+ T cell frequencies in tumor-bearing mice, suggesting that KMT2D deficiency decreases B cell lymphoma recognition by CD8+ T cells.
Our findings contribute to our understanding of how epigenetic changes affect immune surveillance in B cell lymphomas, potentially leading to more targeted and long-lasting therapies for these malignances.
SPECIAL SEMINAR - Dr. Guadalupe SUAREZ - INSERM U1236 MOBIDIC RENNES
"Epigenetic regulation of anti-tumoral CD8+ T cell responses against transposable elements in mature B-cell Lymphomas"
Martes 19 enero 2027, 11:00

200
"Epigenetic regulation of anti-tumoral CD8+ T cell responses against transposable elements in mature B-cell Lymphomas"
Dr. Guadalupe SUAREZ
MCF University of Rennes and INSERM U1236 MOBIDIC RENNES
Abstract
Follicular lymphoma (FL) and large B-cell lymphoma (LBCL) account for over 70% of all lymphoma cases and frequently exhibit mutations in epigenetic regulators such as KMT2D, CREBBP and EZH2, but the impact of these mutations on the recognition of tumor cells by CD8+ T cells is poorly understood. Additionally, transposable elements (TE), which are normally silenced by epigenetic mechanisms, may become re-expressed in cancer, leading to the production of TE-derived neoantigens that can be recognized by the immune system.
Our group investigates how mutations in epigenetic regulators impact CD8+ immune responses in B cell lymphomas with a focus on CD8+ T cell responses to TE-derived antigens, in both patient samples and mouse models. By combining RNAseq analysis of large patient cohorts with immunopeptidomic analyses, we found sets of TEs overexpressed in tumoral B cells that can give rise to peptides presented in MHC-I molecules in B lymphoma samples, showing that TE-derived peptides can be presented in MHC-I molecules in B lymphoma samples. We also found that mutations in KMT2D, CREBBP and EZH2 impact TE expression in FL patient tumors and that treatment of B lymphoma cell lines with the EZH2 inhibitor Tazemetostat, induces the overexpression of specific sets of TEs on EZH2 gain of function mutated cell lines.
To assess the impact of KMT2D mutations on immune responses in B cell lymphomas, we have developed a transplantable syngeneic LBCL mouse model mutated for KMT2D. Analysis of TE expression shows that KMT2D deficiency impacts the expression of several hundreds of TEs. Finally, preliminary results show that KMT2D deficiency reduces tumor-specific CD8+ T cell frequencies in tumor-bearing mice, suggesting that KMT2D deficiency decreases B cell lymphoma recognition by CD8+ T cells.
Our findings contribute to our understanding of how epigenetic changes affect immune surveillance in B cell lymphomas, potentially leading to more targeted and long-lasting therapies for these malignances.